PSMA-PET/CT引导的挽救性放疗用于复发或持续存在且PSA<0.2 ng/ml的前列腺癌
这项回顾性多中心研究评估了PSMA-PET/CT引导的挽救性放疗在根治术后复发或持续PSA且PSA<0.2 ng/ml患者中的疗效。最终队列273例,中位随访31.1个月,2年和3年生化复发无生存率分别为90.1%和79.2%。作者认为PSMA-PET/CT引导可能使这类极低PSA患者获益,表现为较好的BRFS率和较少的放疗野内复发。
要点
- 273例术后PSA<0.2 ng/ml患者接受PSMA-PET/CT引导挽救性放疗,2年BRFS为90.1%、3年为79.2%。
- 精囊侵犯(p=0.019)和PET/CT局部复发(p=0.039)在多因素分析中与生化复发显著相关。
- 16例有放疗后复发模式信息,其中1例复发位于放疗野内。
核心结论
- 这项多中心分析提示,采用PSMA-PET/CT成像指导挽救性放疗可能使术后极低PSA水平患者获益,依据是较好的BRFS率和较少的放疗野内复发。
研究设计与样本
- 回顾性多中心研究,来源为6个国家11个中心的汇总队列(n=1223)。
- 排除挽救性放疗前PSA>0.2 ng/ml或未对前列腺窝行挽救性放疗的患者后,最终队列273例。
- 主要终点为生化复发无生存(BRFS),生化复发定义为挽救性放疗后PSA最低值+0.2 ng/ml。
- 采用Cox回归分析评估临床参数对BRFS的影响,并分析挽救性放疗后复发模式。
主要发现
- 273例中78/273(28.6%)PET/CT示局部复发,48/273(17.6%)示淋巴结复发。
- 前列腺窝最常用挽救性放疗剂量为66-70 Gy(143/273,52.4%)。
- 87/273(31.9%)患者接受盆腔淋巴引流区挽救性放疗,36/273(13.2%)接受雄激素剥夺治疗。
- 中位随访31.1个月(IQR:20-44),60/273(22%)出现生化复发,2年和3年BRFS分别为90.1%和79.2%。
- 多因素分析中,手术精囊侵犯(p=0.019)和PET/CT局部复发(p=0.039)对生化复发有显著影响。
关键数值与推荐
- 生化复发定义为挽救性放疗后PSA最低值+0.2 ng/ml。
- 前列腺窝最常用挽救性放疗剂量为66-70 Gy(143/273,52.4%)。
- 2年和3年BRFS分别为90.1%和79.2%。
- 手术精囊侵犯(p=0.019)和PET/CT局部复发(p=0.039)在多因素分析中与生化复发显著相关。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this retrospective, multicenter study was to assess efficacy of PSMA-PET/CT-guided salvage radiotherapy (sRT) in patients with recurrent or persistent PSA after primary surgery and PSA levels < 0.2 ng/ml. METHODS: The study included patients from a pooled cohort (n = 1223) of 11 centers from 6 countries. Patients with PSA levels > 0.2 ng/ml prior to sRT or without sRT to the prostatic fossa were excluded. The primary study endpoint was biochemical recurrence-free survival (BRFS) and BR was defined as PSA nadir after sRT + 0.2 ng/ml. Cox regression analysis was performed to assess the impact of clinical parameters on BRFS. Recurrence patterns after sRT were analyzed. RESULTS: The final cohort consisted of 273 patients; 78/273 (28.6%) and 48/273 (17.6%) patients had local or nodal recurrence on PET/CT. The most frequently applied sRT dose to the prostatic fossa was 66-70 Gy (n = 143/273, 52.4%). SRT to pelvic lymphatics was delivered in 87/273 (31.9%) patients and androgen deprivation therapy was given to 36/273 (13.2%) patients. After a median follow-up time of 31.1 months (IQR: 20-44), 60/273 (22%) patients had biochemical recurrence. The 2- and 3-year BRFS was 90.1% and 79.2%, respectively. The presence of seminal vesicle invasion in surgery (p = 0.019) and local recurrences in PET/CT (p = 0.039) had a significant impact on BR in multivariate analysis. In 16 patients, information on recurrence patterns on PSMA-PET/CT after sRT was available and one had recurrent disease inside the RT field. CONCLUSION: This multicenter analysis suggests that implementation of PSMA-PET/CT imaging for sRT guidance might be of benefit for patients with very low PSA levels after surgery due to promising BRFS rates and a low number of relapses within the sRT field.
引用
- Solomonidou N, Germanou D, Strouthos I, et al. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml. Eur J Nucl Med Mol Imaging. 2023. PMID: 36905411. doi:10.1007/s00259-023-06185-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。